- Home
- GOSS vs SSP Comparison
GOSS vs SSP Comparison
Compare GOSS & SSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- SSP
- Stock Information
- Founded
- GOSS 2015
- SSP 1878
- Country
- GOSS United States
- SSP United States
- Employees
- GOSS N/A
- SSP N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- SSP Broadcasting
- Sector
- GOSS Health Care
- SSP Industrials
- Exchange
- GOSS Nasdaq
- SSP Nasdaq
- Market Cap
- GOSS 188.6M
- SSP 158.9M
- IPO Year
- GOSS 2019
- SSP 1988
- Fundamental
- Price
- GOSS $0.84
- SSP $2.17
- Analyst Decision
- GOSS Strong Buy
- SSP Buy
- Analyst Count
- GOSS 4
- SSP 2
- Target Price
- GOSS $7.50
- SSP $6.25
- AVG Volume (30 Days)
- GOSS 1.5M
- SSP 1.4M
- Earning Date
- GOSS 05-06-2025
- SSP 05-08-2025
- Dividend Yield
- GOSS N/A
- SSP N/A
- EPS Growth
- GOSS N/A
- SSP N/A
- EPS
- GOSS N/A
- SSP 1.01
- Revenue
- GOSS $114,701,000.00
- SSP $2,509,772,000.00
- Revenue This Year
- GOSS N/A
- SSP N/A
- Revenue Next Year
- GOSS $172.31
- SSP $9.18
- P/E Ratio
- GOSS N/A
- SSP $2.15
- Revenue Growth
- GOSS N/A
- SSP 9.46
- 52 Week Low
- GOSS $0.50
- SSP $1.36
- 52 Week High
- GOSS $1.55
- SSP $4.65
- Technical
- Relative Strength Index (RSI)
- GOSS 37.58
- SSP 43.83
- Support Level
- GOSS $0.80
- SSP $2.01
- Resistance Level
- GOSS $0.88
- SSP $2.37
- Average True Range (ATR)
- GOSS 0.10
- SSP 0.25
- MACD
- GOSS -0.01
- SSP -0.09
- Stochastic Oscillator
- GOSS 20.24
- SSP 13.33
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About SSP E.W. Scripps Company (The)
The E W Scripps Co is a media enterprise with interests in local and national media brands. It owns and operates a collection of daily and community newspapers in medium-sized cities in the southern and western portions of the United States. The company's operating segment includes Local Media, Scripps Networks, and Other. It generates maximum revenue from the Local Media segment. The Local Media segment includes local broadcast stations and their related digital operations.